Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
- 1 August 2003
- journal article
- hematological malignancies
- Published by Elsevier BV in Experimental Hematology
- Vol. 31 (8), 686-692
- https://doi.org/10.1016/s0301-472x(03)00112-7
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit geneBlood, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571Oncogene, 2000
- Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosisExperimental Hematology, 2000
- Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast CellsJournal of Investigative Dermatology, 2000
- Activating c-kit Gene Mutations in Human Germ Cell TumorsThe American Journal of Pathology, 1999
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces ApoptosisBlood Cells, Molecules, and Diseases, 1997
- Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasmNature Genetics, 1996